Novel Violet Laser Fluorochrome Conjugates

Brilliant Violet 421™, superior to Pacific Blue™, BD Horizon™ V450

Brilliant Violet 421™ is the first in a series of polymer-based fluorochromes, developed from Nobel Prize-winning chemistry[1] that will revolutionize flow cytometry. With a dramatically improved signal-to-noise ratio, Brilliant Violet 421™ can increase assay sensitivity by logarithmic orders of magnitude without increasing background or spill-over, making it ideal for detecting rare cell populations and weakly expressed cell markers.

1. The Nobel Prize in Chemistry, 2000: A. Heeger, A.G. MacDiarmid, H. Shirakawa.

Stain Index

Specificity /Clone	Fluorochrome	Laser Excitation	Stain Index
CD3/UCHT1	Brilliant Violet 421™	405 nm	262
CD3/UCHT1	PE	561 nm	170
CD3/UCHT1	Pacific Blue™	405 nm	59
CD3/UCHT1	BD Horizon™ V450	405 nm	56

RBC-lysed whole blood cells were stained with anti-CD3 conjugated to the above fluorochromes and run on the BD™ LSR II flow cytometer. The stain index values indicated are derived at the optimal concentration for each conjugate.

Learn More at Immunology 2011™ — Stop by our Booth: #400

So Bright, It's Brilliant: Brilliant Violet™ Antibody Conjugates

Exhibitor Workshops: May 14 & 15, 1:30 pm — ***Product Showcases:*** May 14 & 15, 10:00 am

Poster Session: May 14, 2:30 pm – Meet our Scientists

#B609, Brilliant Violet 421™ and Brilliant Violet 570™ antibody conjugates deliver consistent and superior performance on violet-laser equipped flow cytometers with varied specifications

#B631, Brighter is better: the introduction of Brilliant Violet™ conjugated antibodies for flow cytometry

Visit us at **biolegend.com** for more information about Brilliant Violet™ antibodies.

Powered by Sirigen

BioLegend®
The path to legendary discovery™

Toll-Free Tel: (US & Canada): 1.877.BIOLEGEND (246.5343)
Tel: 858.768.5800
biolegend.com

08-0009-00

The PROOF is in GAMUNEX-C

The *first and only* IG* therapy with both IV† and SC‡ routes of administration in Primary Immunodeficiency (PI)

Important Safety Information for GAMUNEX-C

Gamunex-C, Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified, is indicated for the treatment of primary humoral immunodeficiency disease (PI), idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Gamunex-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer Gamunex-C at the minimum concentration available and the minimum infusion rate practicable.

Gamunex-C is contraindicated in individuals with acute severe hypersensitivity reactions to Immune Globulin (Human). It is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity.

Gamunex-C is not approved for subcutaneous use in patients with ITP or CIDP. **Due to the potential risk of hematoma formation, Gamunex-C should not be administered subcutaneously in patients with ITP.**

Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV therapy.

Thrombotic events have been reported in association with IGIV. Patients at risk for thrombotic events may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization and/or known or suspected hyperviscosity.

There have been reports of noncardiogenic pulmonary edema [Transfusion-Related Lung Injury (TRALI)], hemolytic anemia, and aseptic meningitis in patients administered with IGIV.

The high dose regimen (1g/kg x 1-2 days) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern.

Gamunex-C is made from human plasma. Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation.

In clinical studies, the most common adverse reactions with Gamunex-C were headache, fever, chills, hypertension, rash, nausea, and asthenia (in CIDP); headache, cough, injection site reaction, nausea, pharyngitis, and urticaria with intravenous use (in PI) and infusion site reactions, headache, fatigue, arthralgia and pyrexia with subcutaneous use (in PI); and headache, vomiting, fever, nausea, back pain, and rash (in ITP).

The most serious adverse reactions in clinical studies were pulmonary embolism (PE) in one subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in one subject (in PI), and myocarditis in one subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).

*IG=Immune globulin; †IV=Intravenous; ‡SC=Subcutaneous.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see adjacent page for brief summary of GAMUNEX-C full Prescribing Information.

gamunex®-C
immune globulin injection (human), 10%
caprylate/chromatography purified

Evidence based. Patient proven.

Talecris BIOTHERAPEUTICS

To get GAMUNEX-C call 1-888-MY-GAMUNEX (694-2686) USA Customer Service 1-800-243-4153 Clinical Communications 1-800-520-2807 Reimbursement *Help*line 1-877-827-3462

GAMUNEX®-C

Immune Globulin Injection (Human) 10% Caprylate/Chromatography Purified

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use GAMUNEX®-C safely and effectively. See full prescribing information for GAMUNEX-C.

GAMUNEX-C, [Immune Globulin Injection (Human) 10% Caprylate/Chromatography Purified]

Initial U.S. Approval: 2003

WARNING: ACUTE RENAL DYSFUNCTION and FAILURE

See full prescribing information for complete boxed warning.

- **Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients.**
- **Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMUNEX-C does not contain sucrose.**
- **For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.**

----------INDICATIONS AND USAGE----------

GAMUNEX-C is an immune globulin injection (human) 10% liquid indicated for treatment of:

- Primary Humoral Immunodeficiency (PI)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

----------CONTRAINDICATIONS ----------

- Anaphylactic or severe systemic reactions to human immunoglobulin
- IgA deficient patients with antibodies against IgA and a history of hypersensitivity

----------WARNINGS AND PRECAUTIONS----------

- IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions.
- Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of developing acute renal failure.
- GAMUNEX-C is not approved for subcutaneous use in ITP patients. Due to a potential risk of hematoma formation, do not administer GAMUNEX-C subcutaneously in patients with ITP.
- Hyperproteinemia, with resultant changes in serum viscosity and electrolyte imbalances may occur in patients receiving IGIV therapy.
- Thrombotic events have occurred in patients receiving IGIV therapy. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for those at risk of hyperviscosity.
- Aseptic Meningitis Syndrome (AMS) has been reported with GAMUNEX-C and other IGIV treatments, especially with high doses or rapid infusion.
- Hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration. Monitor patients for hemolysis and hemolytic anemia.
- Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).
- Volume overload
- GAMUNEX-C is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
- Passive transfer of antibodies may confound serologic testing.

----------ADVERSE REACTIONS ----------

- **PI** – The most common adverse reactions (≥5%) with intravenous use of GAMUNEX-C were headache, cough, injection site reaction, nausea, pharyngitis and urticaria. The most common adverse reactions (≥5%) with subcutaneous use of GAMUNEX-C were infusion site reactions, headache, fatigue, arthralgia and pyrexia.
- **ITP** – The most common adverse reactions during clinical trials (reported in ≥5% of subjects) were headache, vomiting, fever, nausea, back pain and rash.
- **CIDP** – The most common adverse reactions during clinical trials (reported in ≥5% of subjects) were headache, fever, chills, hypertension, rash, nausea and asthenia.

To report SUSPECTED ADVERSE REACTIONS, contact Talecris Biotherapeutics, Inc. at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

----------DRUG INTERACTIONS ----------

- The passive transfer of antibodies may transiently interfere with the response to live viral vaccines, such as measles, mumps and rubella. Passive transfer of antibodies may confound serologic testing.

----------USE IN SPECIFIC POPULATIONS ----------

- Pregnancy: no human or animal data. Use only if clearly needed.
- Geriatric: In patients over 65 years of age do not exceed the recommended dose, and infuse GAMUNEX-C at the minimum infusion rate practicable.

Talecris BIOTHERAPEUTICS

Talecris Biotherapeutics, Inc.
Research Triangle Park, NC 27709 USA
U.S. License No. 1716

08939771/08939782-BS
Revised: October 2010

So Bright, It's Brilliant





Brilliant Violet™ Antibody Conjugates

Brilliant Violet 421™, superior to Pacific Blue™, BD Horizon™ V450

Novel Violet Laser Fluorochrome Conjugates

- >10X Brighter than Pacific Blue™
- No special buffers required
- Stable to Fixation
- Extensive Selection of Conjugates
- Excellent Photostability
- Great Pricing

Brilliant Violet 421™ is the first in a series of polymer-based fluorochromes, developed from Nobel Prize-winning chemistry[1] that will revolutionize flow cytometry. With a dramatically improved signal-to-noise ratio, Brilliant Violet 421™ can increase assay sensitivity by logarithmic orders of magnitude without increasing background or spill-over, making it ideal for detecting rare cell populations and weakly expressed cell markers.

Stain Index

Specificity /Clone	Fluorochrome	Laser Excitation	Stain Index
CD3/UCHT1	Brilliant Violet 421™	405 nm	262
CD3/UCHT1	PE	561 nm	170
CD3/UCHT1	Pacific Blue™	405 nm	59
CD3/UCHT1	BD Horizon™ V450	405 nm	56

RBC-lysed whole blood cells were stained with anti-CD3 conjugated to the above fluorochromes and run on the BD™ LSR II flow cytometer. The stain index values indicated are derived at the optimal concentration for each conjugate.

1. The Nobel Prize in Chemistry, 2000: A. Heeger, A.G. MacDiarmid, H. Shirakawa.

Visit us at **biolegend.com** for more information about Brilliant Violet 421™ antibodies.

Powered by Sirigen

BioLegend®

Toll-Free Tel: (US & Canada): 1.877.BIOLEGEND (246.5343)
Tel: 858.768.5800
biolegend.com

08-0005-10

cell sciences®

cytokine center

Browse our web site of recombinant proteins, including cytokines, growth factors, chemokines and neurotrophins. Daily shipping and competitive pricing are offered. Bulk quantities of many proteins available. Cell Sciences also carries corresponding antibodies and ELISA kits.

www.cellsciences.com

LIST OF PROTEINS

4-1BBL
4-1BB Receptor
6 Ckine
ACAD8
ACAT2
gAcrp30/Adipolean
Activin A
ACY1
ADAT1
Adiponectin
ADRP
AITRL
Akt1
Alpha-Feto Protein (AFP)
Alpha-Galactosidase A
Angiopoietin-1 (Ang-1)
Angiopoietin-2 (Ang-2)
Angiostatin K1-3
Annexin-V
apo-SAA
Apoliprotein A-1
Apoliprotein E2
Apoliprotein E3
Apoliprotein E4
APRIL
Artemin
ATF2
Aurora A
Aurora B
BAFF
BAFF Receptor
BCA-1 / BLC / CXCL13
BCMA
BD-1
BD-2
BD-3
BDNF
Bivalirudin
BMP-2
BMP-4
BMP-7
BMP-13
sBMPR-1A
Brain Natriuretic Protein
BRAK
Breast Tumor Antigen
C5a
C5L2 Peptide
C-10
C-Reactive Protein
C-Src
Calbindin D-9K
Calbindin D-28K
Calbindin D-29K
Calmodulin
Calcitonin Acetate
Carbonic Anhydrase III
Carcino-embryonic Antigen
Cardiotrophin-1
Caspase-3
Caspase-6
CD4
CD14
CD22
CD40 Ligand / TRAP
CD95 / sFas Ligand
CD105 / Endoglin
CHIPS
CNTF
Collagen
CREB
CTACK/CCL27
CTGF
CTGFL/WISP-2
CTLA-4/Fc
CXCL16
Cytokeratin 8
DEP-1
Desmopressin
Disulfide Oxidoreductase
E-selectin
ECGF
EGF
Elafin/SKALP
EMAP-II
ENA-78
Endostatin
Enteropeptidase
Eotaxin
Eotaxin-2
Eotaxin-3 (TSC)
EPHB2
EPHB4
Eptifbatide
Erk-2
Erythropoietin (EPO)
Exodus-2
Fas Ligand
Fas Receptor
FGF-1 (acidic)
FGF-2 (basic)
FGF-4
FGF-5
FGF-6
FGF-7/ KGF
FGF-8
FGF-9
FGF-10
FGF-16
FGF-17
FGF-18
FGF-19
FGF-20
sFGFR-1 (IIIc) / Fc Chimera
sFGFR-2 (IIIc) / Fc Chimera
sFGFR-3 / Fc Chimera
sFGFR-4 / Fc Chimera
sFlt-1 (native)
sFlt-1 (D3)
sFlt-1 (D4)
sFlt-1 (D5)
sFlt-1 (D7)
Flt3-Ligand
sFlt-4
sFlt-4/ Fc Chimera
Follistatin
FSH
Fractalkine/ CX3C
G-CSF
α-Galactosidase A
Galectin-1
Galectin-3
Gastrointestinal CA
GCP-2
GDF-3
GDF-9
GDF-11
GDNF
GLP-1
Glucagon
Goserelin
GM-CSF
GPBB
GROα
GROβ
GROγ
GRO/MGSA
Growth Hormone
Growth Hormone BP
GST-p21/WAF-1
HB-EGF
HCC-1
HGF
Histdyl-tRNA synthetase
Histrelin
HRG1-β1
I-309
I-TAC
IFN-α
IFN-α A
IFN-α 2a
IFN-α 2b
IFN-β
IFN-γ
IFN-Omega
IGF-I
IGF-II
proIGF-II
IGFBP-1
IGFBP-2
IGFBP-3
IGFBP-4
IGFBP-4
IGFBP-5
IGFBP-6
IGFBP-7
IL-1α
IL-1β
IL-2
IL-3
IL-4
sIL-4 Receptor
IL-5
IL-6
sIL-6 Receptor
IL-7
IL-8 (72 a.a.)
IL-8 (77 a.a.)
IL-9
IL-10
IL-11
IL-12
IL-13
IL-13 analog
IL-15
IL-16 (121 a.a.)
IL-16 (130 a.a.)
IL-17
IL-17B
IL-17D
IL-17E
IL-17F
IL-19
IL-20
IL-22
IL-31
Insulin
IP-10
JE
JNK2a1
JNK2a2
KC / CXCL1
KGF
L-asparaginase
LAG-1
LALF Peptide
LAR-PTP
LC-1
LBP
LD-78β
LDH
LEC/NCC-4
Leptin
LIGHT
LIX
LKM
LL-37
Lymphotactin
sLYVE-1
M-CSF
MCP-1 (MCAF)
MCP-2
MCP-3
MCP-4
MCP-5
MDC (67 a.a.)
MDC (69 a.a.)
MDH
MEC
Mek-1
MIA
Midkine
MIG / CXCL9
MIP-1α / CCL3
MIP-1β / CCL4
MIP-3 / CCL23
MIP-3α / CCL20
MIP-3β / CCL19
MIP-4 (PARC) / CCL18
MIP-5 / CCL15
MMP-3
MMP-7
MMP-13
Myostatin
Nanog
NAP-2
Neurturin
NFAT-1
beta-NGF
NOGGIN
NOV
NP-1
NT-1/BCSF-3
NT-3
NT-4
Ocreotide
Oncostatin M
Osteoprotegerin (OPG)
OTOR
Oxytocin
p38-α
Parathyroid Hormone
PDGF-AA
PDGF-AB
PDGF-BB
Persephin
PF-4
PIGF-1
PIGF-2
PKA α-subunit
PKC-α
PKC-γ
Pleiotrophin
PLGF-1
Polymyxin B (PMB)
PRAS40
PRL-1
PRL-2
PRL-3
Prokineticin-2
Prolactin
Protirelin
PTHrP
PTP1B
PTP-IA2
PTP-MEG2
PTP-PEST
sRANK
sRANKL
RANTES
RELM-α
RELM-β
Resistin
RPTPβ
RPTPγ
RPTPμ
SCF
SCGF-α
SCGF-β
SDF-1α
SDF-1β
Secretin
SF20
SHP-2
STAT1
c-Src
TACI
TARC
TC-PTP
TECK
TFF2
TGF-α
TGF-β1
TGF-β2
TGF-β3
Thymosin α1
sTIE-1/Fc Chimera
sTIE-2/Fc Chimera
TL-1A
TNF-α
TNF-β
sTNFR1
sTNFR2
TPO
TRAIL/Apo2L
sTRAIL R-1 (DR4)
sTRAIL R-2 (DR5)
TSH
TSLP
TWEAK
TWEAK Receptor
Urokinase
VEGF121
VEGF145
VEGF165
VEGF-C
VEGF-C I525
EG-VEGF
VEGF-E
HB-VEGF-E
sVEGFR-1
sVEGFR-2
sVEGFR-3
WISP-1
WISP-2
WISP-3
WNT-1

CELL SCIENCES INC • 480 NEPONSET STREET, BUILDING 12A, CANTON, MA 02021 • INFO@CELLSCIENCES.COM

TOLL FREE: (888) 769-1246 • TEL: (781) 828-0610 • FAX: (781) 828-0542 • WEB WWW.CELLSCIENCES.COM

IMGENEX
Bridging Innate & Adaptive Immunity
www.imgenex.com

Immune/Inflammatory Signaling Pathways + DC-T Cell Immunoregulatory Network

New Antibodies, Reagents & ELISA Kits

NEW **Cytokine ELISA Kits and Recombinant Proteins**
IL-17A, IL-17AF, Bioactive IL-35 Recombinant Protein, EBI3, IL-33, MIP-3α

NEW **Inflammatory/Immune Signaling**
Gfi-1, GAB1, HMGB1, MyD88, RAGE, Ifi204, Ifi202b

NEW **TLRs and Innate Immune Receptors**
TLR7, Dectin-2, RIG-I, NALP3

NEW **DC-T Cell Network**
BDCA-2, CD123, ILT7



*IL-35 (human and mouse) is protected as an exclusive world-wide license of IMGENEX Corporation.
IL-35 products are for research use only, resale is legally prohibited without written consent and agreement with IMGENEX Corporation.

TLRSystem™

DC-T Cell Network

Signaling Pathways

A to Z provider of Immune/Inflammatory Signaling Pathway Molecules & Receptors

(selected listing below)

- ACT1
- AKT1
- AKT2
- AKT3
- BDCA-2
- Caspase-1
- CD123
- Dectin-2
- EBI3
- FOXP3
- GITR
- GITRL
- Ifi202b
- Ifi204
- IκBα
- IKKα
- IKKβ
- IKKγ
- IL-17
- IL-33
- IL-35
- ILT7
- IRAK-1
- IRAK-2
- IRAK-4
- KLF4
- MD-1
- MD-2
- MIP-3α
- MyD88
- NALP3
- NF-κB/p65
- NF-κB Peptide Inhibitors
- PGRP-1α
- PGRP-1β
- PGRP-S
- RAGE
- RIG-I
- RORγ/RORγ (t)
- SHP-1
- SIGIRR
- SLP76
- ST2/IL1RL1
- ST2V
- SYK
- TBK1
- TIM3 (mouse & human)
- TLRs 1-13
- TLR Ligands/Agonists
- TRIF
- Tyk2
- ZAP-70

Plus many more...

Validated Platforms

- IHC
- Flow Cytometry
- Functional Assays
- ELISA
- Western Blot

www.imgenex.com

Toll-free (888) 723-4363
Fax (858) 642-0937
Email info@imgenex.com



Introducing
High-Throughput HLA Typing
With the GS FLX and GS Junior Sequencing Systems



Identify HLA haplotypes of multiple samples in a single 454 Sequencing run. Use Roche's new **GS GType HLA Primer Sets** to simplify sample preparation, sequence multiple HLA exons, and perform a high-resolution assignment of both alleles.

- **Accurately discriminate variants** using 454 software that is compatible with HLA genotyping tools (*e.g.*, Conexio).
- **Research disease-association patterns**.
- **Discover polymorphic regions within the human genome** for research on infectious disease, cancer, and autoimmune diseases.
- **Capture critical phase information of polymorphic HLA regions** using 454 Sequencing long reads (>300 bp).

To learn more, visit *www.454.com*

◀ **HLA Region (Human Leukocyte Antigen).**

454 SEQUENCING

For life science research only.
Not for use in diagnostic procedures.

Roche Diagnostics Corporation
Roche Applied Science
Indianapolis, Indiana

Roche

Cytek Automatic Micro-Sampling System (AMS)



A cost-effective way to perform rapid acquisition for your flow cytometry samples

INCREASE LAB PRODUCTIVITY

Run a 96-well plate in as little as 15 minutes. The walk-away operation frees lab personnel from loading tubes.

INTUITIVE SOFTWARE

Our easy to use AMS plate-mapping software allows the user to setup their experiment away from the cytometer, making available valuable cytometer acquisition time. Cytek AMS software is available for both MAC and PC.

AUTOMATED DEPENDABILITY

Our uncomplicated design gives users the work-horse reliability they need, as evidenced by over ten years of operation in labs.

SUPERIOR SUPPORT

All systems come with a one-year warranty, and are backed by a highly trained team of technical specialists.

Cytek FLOW CYTOMETRY PRODUCTS

CONTACT US For more information, email us at sales@cytekdev.com or visit us on the web at www.cytekflow.com

Rafick-Pierre Sékaly, Ph.D.
Co-Director and Scientific Director
VGTI–Florida

I am not a paper pusher.

I push scientific boundaries, not paper.
DNA is the only fine print I care for;
everything else is a distraction.

Your core business is immunology, not recruitment, government relations or tax accounting. If you want to dispense with those distractions and focus on what you do best, then take a look at our immunology research park, the Tradition Center for Innovation.

We offer a specialized research environment where park owners, local government and your neighbors are all focused on immunology discovery. This committed partnership can:

- Expedite building permits for new developments
- Facilitate incentives and tax breaks
- Provide access to the resources you need for clinical trials

We have already secured anchor immunology members and are now seeking others. If you want to be a part of this collaborative environment, visit our website at *www.tciflorida.com* or call Andrew Favata at (772) 345-3515 to organize a tour.

accelerating life science.
make it your TRADITION.

TRADITION CENTER FOR INNOVATION

INNATE IMMUNITY

TLR LIGANDS

Pick from our extensive library

Toll-like receptor (TLR) ligands are essential tools for studying the role of TLRs in innate immunity. TLR ligands are conserved microbial molecules that differentially activate the TLRs. As the TLR specialist, InvivoGen develops and produces a vast choice of high quality TLR ligands, validated in-house and tested for the presence of endotoxins.

- Ever-expanding collection of TLR ligands
- Include TLR agonists and antagonists
- Validated for TLR stimulation
- Endotoxin tested

TLR Ligands and more:

- TLR2 ligands
- TLR3 ligands
- TLR4 ligands
- TLR5 ligands
- TLR7 ligands
- TLR7 ligands
- TLR7/8 ligands
- TLR9 ligands
- Dectin-1 ligands
- NOD1/2 ligands
- RIG-I/MDA5 ligands
- Labeled ligands

To learn more, visit:

www.invivogen.com/innate-immunity-pamps

InvivoGen
INNOVATION WITHIN REACH

The Future is Here …

… and it looks **Brilliant!**

We're changing the future of flow cytometry with Brilliant Violet™ technology.

It's time to:

- Experience the next generation of fluorescence tools
- Expand the utility of your violet laser
- Discover new choices for your multi-color panels

Learn more at…
AAI 2011 • San Francisco, CA • Booth #639
or
www.i-cyt.com/brilliant

iCyt®

A Sony Group Company

BD Biosciences flow cytometry systems








BD

Helping all people live healthy lives

In a perpetual state of the art.

At BD Biosciences, we're always thinking about what's next in flow cytometry and multicolor analysis. Since commercializing the first cell sorter in 1973, we've been delivering flow cytometry systems that are more powerful, more dependable, and easier to use.

We innovate to keep you in a perpetual state of the art, because when we do, your work goes more smoothly, clearing the way to faster discovery and better clinical care.

From special order systems that support advanced research to clinical solutions that streamline care, you can depend on BD systems to make your job easier, your workflow more efficient, and your results more reliable, today and tomorrow.

Innovation is built in.
You can depend on it.

bdbiosciences.com/innovation

BD Biosciences
2350 Qume Drive
San Jose, CA 95131
bdbiosciences.com